A monoclonal antibody labeled with 177Lu and targeting anticlaudin 6 is being explored for use in targeted therapy. This approach is specifically being investigated for its potential application in treating esophageal cancer. The use of this labeled antibody may offer a new direction for therapy in this type of cancer.